Look inside at BBio

BILTHOVEN, The Netherlands, June 30, 2023 — Bilthoven Biologicals (BBio) today announced that it is one of the selected companies in Europe to be granted a pandemic preparedness contract by the European Commission. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of viral vector vaccines in emergency situations in Europe.

When you ask the people in our U3 bacterial production facility what is driving the increase in productivity in their plant, they all tell the same story. It is driven by working smarter. It is not the objective of one person to aim for this; no, all 22 persons that work in U3 are actively looking for ways to improve production processes, all the time.

The Serum Institute of India Pvt., Ltd., the Supervisory Board and CEO of Bilthoven Biologicals B.V. have agreed that the CEO steps down as Managing Director on March 31st, 2023.

In November 2022, a Bilthoven Biologicals employee became infected with the polio virus during his work. The company then ceased activities with active polio virus. An investigation into the cause and improvement actions were successfully carried out. On February 6, the company will restart production of polio vaccines.

This message is an update after the polio virus infection of an employee at Bilthoven Biologicals. After an employee of Bilthoven Biologicals became infected with the polio virus, he was placed in isolation. On January 11, 2023, the employee was able to get out of isolation again. The employee no longer carries the virus and can therefore no longer infect others. The virus was also not found in the contacts of the employee that was examined.

One of Bilthoven Biologicals’ (BBio) employees became infected with the polio virus during his work. Until the cause is completely clear and all processes have been checked again, BBio will cease activities with active polio virus.

A new annual event is scheduled to kick off on 14 and 15 October 2021: Utrecht Science Week. The central theme is: ‘Creating a healthy, sustainable society together’.

Decades of invention have built a strong legacy for vaccines in the Netherlands. From Bilthoven’s historic contributions to recent investments from Janssen Inc. & Moderna, learn how the Dutch are advancing the future of vaccines. An article from our partner Invest in Holland.

Maarten Manders is director Marketing and Sales at BBio. He explains how a small company from Bilthoven in the Netherlands can have a significant impact on the fight against polio worldwide.